Valuation: Erasca, Inc.

Market Cap 6.34B 5.5B 5.15B 4.71B 8.9B 604B 9.02B 60.29B 23.66B 302B 23.81B 23.29B 1,005B P/E 2026 *
-19.2x
P/E 2027 * -31.9x
Enterprise Value 5.82B 5.05B 4.73B 4.33B 8.17B 555B 8.28B 55.34B 21.72B 277B 21.86B 21.38B 922B EV / Sales 2026 *
-
EV / Sales 2027 * 11,533x
Free-Float
90.32%
Yield 2026 *
-
Yield 2027 * -
1 day-1.88%
1 week-2.19%
Current month+0.66%
1 month-3.08%
3 months+67.61%
6 months+48.66%
Current year+391.13%
1 week 17.08
Extreme 17.08
19
1 month 17.08
Extreme 17.08
21.6
Current year 3.36
Extreme 3.36
24.28
1 year 1.33
Extreme 1.3301
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 28/02/2019
Director of Finance/CFO 43 06/01/2021
Chief Tech/Sci/R&D Officer - 24/05/2022
Director TitleAgeSince
Chairman 54 30/09/2018
Director/Board Member 79 31/05/2018
Director/Board Member 58 01/07/2018
Date Insider Type Main position Quantity % Market Cap.
26/06/26 Free

Director

29,888 0.0096%
29/01/26 Free

General Counsel

560,000 0.1974%
29/01/26 Free

Chief Executive Officer

2,000,000 0.7049%
Change 5-day change 1-year change 3-year change Capi.($)
-1.88%-2.19%+1,177.62%+600.00% 6.46B
+0.93%-0.63%+3.89%+14.93% 48.57B
+0.26%+2.93%+439.43%+533.80% 41.95B
-1.53%-2.25%+30.95%+7.15% 38.85B
+0.69%+2.40%+10.48%+63.05% 37.24B
+2.47%+2.63%+14.71%+48.37% 30.67B
-0.47%+1.16%+35.93%+126.09% 16.41B
+2.31%-0.49% - - 16.1B
+0.29%+1.87%+8.17%+18.60% 13.97B
-1.43%-2.63%+3.70%-36.38% 12.62B
Average +0.16%+0.05%+191.65%+152.84% 26.28B
Weighted average by Cap. +0.39%+0.17%+117.65%+133.64%

Financials

2026 *2027 *
Net sales - 500K 434K 406K 372K 702K 47.63M 711K 4.75M 1.87M 23.8M 1.88M 1.84M 79.21M
Net income -300M -260M -243M -223M -420M -28.54B -426M -2.85B -1.12B -14.26B -1.12B -1.1B -47.46B -195M -169M -158M -145M -273M -18.54B -277M -1.85B -726M -9.26B -731M -715M -30.83B
Net Debt -520M -452M -423M -387M -730M -49.56B -740M -4.95B -1.94B -24.76B -1.95B -1.91B -82.42B -576M -500M -468M -428M -808M -54.84B -818M -5.47B -2.15B -27.4B -2.16B -2.11B -91.2B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
06/08/26 US$18.27 -1.88% 2,427,096
05/08/26 US$18.62 +1.31% 3,104,177
04/08/26 US$18.38 +3.03% 4,759,060
03/08/26 US$17.84 -1.71% 2,751,851
31/07/26 US$18.15 -2.84% 2,696,841
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
18.27USD
Average target price
22.80USD
Spread / Average Target
+24.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock